Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 30;12(6):e1005632.
doi: 10.1371/journal.ppat.1005632. eCollection 2016 Jun.

Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design

Zachary T Freeman  1 , Andrea L Cox  1
Affiliations
Review

Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design

Zachary T Freeman et al. PLoS Pathog. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Hepatitis C virus vaccine development has been hindered by few representative models and the recent significant limitation in use of chimpanzees as a model.
Although it is not completely understood what confers protection, research in HCV-infected humans who control infection has enhanced understanding of the immune response and informed vaccine design. Two candidate vaccines have been tested in humans. The E1E2 glycoprotein and Chimp Adenovirus 3 Nonstructural (Ad Ch3 NS)/Modified Vaccinia Ankara NS (MVA NS) vaccines have elicited robust immune responses in healthy humans that resemble immune correlates of clearance. The Ad Ch3 NS/MVA NS vaccine is in a phase II clinical trial in people who inject drugs (PWID) to determine if it confers protective immunity. Immune responses identified in those protected from HCV in vaccine trials can be assessed in natural infection as well to determine if they mediate disease control.
See this image and copyright information in PMC

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. 10.1002/hep.26141 . - DOI - PubMed
    1. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Annals of internal medicine. 2013;158:235–45. 10.7326/0003-4819-158-4-201302190-00003 . - DOI - PMC - PubMed
    1. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. 10.1038/nature08463 - DOI - PMC - PubMed
    1. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging Epidemic of Hepatitis C Virus Infections Among Young Non-Urban Persons who Inject Drugs in the United States, 2006–2012. Clin Infect Dis. 2014. Epub 2014/08/13. 10.1093/cid/ciu643 . - DOI - PubMed
    1. Gravitz L. Introduction: a smouldering public-health crisis. Nature. 2011;474(7350):S2–4. Epub 2011/07/20. 10.1038/474S2a . - DOI - PubMed

Substances